{
    "clinical_study": {
        "@rank": "122584", 
        "arm_group": [
            {
                "arm_group_label": "Attention Deficit Hyperactivity Disorder", 
                "arm_group_type": "Experimental", 
                "description": "Adult males with Attention Deficit Hyperactivity disorder will participate in a crossover design and receive both methylphenidate and placebo on two separate days."
            }, 
            {
                "arm_group_label": "Healthy adults", 
                "arm_group_type": "Experimental", 
                "description": "Healthy male adults will participate in a crossover design and receive both methylphenidate and placebo on two separate days."
            }
        ], 
        "brief_summary": {
            "textblock": "The goal of the study is to use graph theory to examine how the organization of the\n      functional brain network may be altered by the administration of methylphenidate. This\n      effect is to be compared between methylphenidate intake and placebo intake, as well as\n      between healthy adult males and adult males with a diagnosis of Attention Deficit\n      Hyperactivity Disorder."
        }, 
        "brief_title": "Effect of Methylphenidate on Connectivity", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Attention Deficit Hyperactivity Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Attention Deficit Disorder with Hyperactivity", 
                "Hyperkinesis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male sex\n\n          -  Written informed consent\n\n          -  For the Attention Deficit Hyperactivity Disorder group only: a diagnosis of Attention\n             Deficit Hyperactivity Disorder\n\n        Exclusion Criteria:\n\n          -  Age under 18 or > 40\n\n          -  Previous or current medical, psychiatric, or neurological problems (with\n             exception of Attention Deficit Hyperactivity Disorder group)\n\n          -  Use of psychotropic medication\n\n          -  Use of recreational drugs in the two weeks before start of the study\n\n          -  Consuming an equivalent of > 5 cups of coffee per day\n\n          -  Consuming three or more alcohol units per day\n\n          -  The presence of one or more of the contraindications or warnings against the study\n             drug as listed in the Summary of Product Characteristic\n\n          -  Presence of any contraindication to Magnetic Resonance Imaging scanning (e.g.\n             implanted metallic object or electronic device)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764672", 
            "org_study_id": "2012-005339-95", 
            "secondary_id": "NL42603.041.12"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Attention Deficit Hyperactivity Disorder", 
                    "Healthy adults"
                ], 
                "description": "Oral dose 40mg (2 x 20mg)", 
                "intervention_name": "Methylphenidate", 
                "intervention_type": "Drug", 
                "other_name": "Ritalin"
            }, 
            {
                "arm_group_label": [
                    "Attention Deficit Hyperactivity Disorder", 
                    "Healthy adults"
                ], 
                "description": "Oral intake of 2 placebo tablets", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methylphenidate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Attention Deficit Hyperactivity Disorder", 
            "Healthy Adults", 
            "Methylphenidate", 
            "Functional connectivity", 
            "Functional Magnetic Resonance Imaging"
        ], 
        "lastchanged_date": "February 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Utrecht", 
                    "country": "Netherlands", 
                    "zip": "3584 CX"
                }, 
                "name": "UMC Utrecht"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Methylphenidate on Resting State Connectivity in Healthy Controls and in Adults With Attention Deficit Hyperactivity Disorder.", 
        "overall_official": [
            {
                "affiliation": "UMC Utrecht", 
                "last_name": "Iris EC Sommer, Prof, Dr.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "UMC Utrecht", 
                "last_name": "Martijn P Van den Heuvel, Dr.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective in the current trial is to use graph theory to examine how the organization of the functional brain network may be altered by the administration of methylphenidate. The main question we intend to answer in this study, is whether, and if so to what extent, methylphenidate affects the organization of brain networks.", 
            "measure": "The difference in functional connectivity as measured with functional Magnetic Resonance Imaging between participants who ingested methylphenidate and those who ingested placebo.", 
            "safety_issue": "No", 
            "time_frame": "After the last patient has completed the last visit, which is expected to be two years after the start of the study"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764672"
        }, 
        "responsible_party": {
            "investigator_affiliation": "UMC Utrecht", 
            "investigator_full_name": "Iris Sommer", 
            "investigator_title": "Prof.Dr.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "To examine if any of the effects on brain connectivity differ between participants with Attention Deficit Hyperactivity Disorder versus healthy controls.", 
                "measure": "The difference in functional connectivity as measured by functional Magnetic Resonance Imaging between participants with Attention Deficit Hyperactivity Disorder and healthy controls.", 
                "safety_issue": "No", 
                "time_frame": "After the last patient has completed the last visit, which is expected to be two years after the start of the study"
            }, 
            {
                "description": "To examine how a reorganization of brain networks as described in the primary objective is related to improvements in cognitive performance and to blood levels of methylphenidate.", 
                "measure": "The correlation of graph metrics (as a measure of functional network organization) with performance (scores) on cognitive tasks and blood levels of methylphenidate.", 
                "safety_issue": "No", 
                "time_frame": "After the last patient has completed the last visit, which is expected to be two years after the start of the study"
            }, 
            {
                "description": "To examine if certain network structures of the brain, such as cortical thickness and white matter volume, are related to susceptibility to medication efficacy and if the structural qualities are related to cognitive performance.", 
                "measure": "The correlation of whole brain cortical thickness and white matter volume as measured with Magnetic Resonance Imaging with both graph metrics as measured with functional Magnetic Resonance Imaging and scores on cognitive tests.", 
                "safety_issue": "No", 
                "time_frame": "After the last patient has completed the last visit, which is expected to be two years after the start of the study"
            }
        ], 
        "source": "UMC Utrecht", 
        "sponsors": {
            "collaborator": {
                "agency": "Hersenstichting Nederland", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Iris Sommer", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}